BCPC — Q3 2026 Financial Report Analysis

Balchem Q3 2026: sales +8.6% and EPS +17.7%, with Human Nutrition selling far more at lower prices and Animal Nutrition's margin rising again

Balchem, which makes specialty ingredients for food, supplements, animal feed and medical sterilisation, reported third-quarter 2026 net sales of $290.7 million, up 8.6% from $267.6 million a year earlier. Net earnings rose 16.0% to $46.7 million and diluted earnings per share (EPS — profit divided by the number of shares) rose from $1.24 to $1.46. Profit grew about twice as fast as sales for three reasons: a better gross margin, a one-time $4.0 million legal settlement gain (partly offset by a $1.9 million equipment write-off), and fewer shares outstanding after buybacks. Sales growth slowed from 11.2% in Q2, and the mix of growth changed: the largest segment, Human Nutrition & Health, sold 12.7% more by volume but at prices 4.4% lower.

Key figures

Gross margin is what is left of sales after the direct cost of making the product. Operating margin is the share of sales left after paying for production and running the business, before interest and tax.

For the first nine months of 2026, sales were $845.4 million (+9.3%), net earnings $131.6 million (+13.8%) and diluted EPS $4.09 versus $3.54 (+15.5%).

Segment performance

"Volume/mix" means selling more product, or a richer blend of products; "price" is the effect of changes in average selling prices; "FX" is the effect of currency moves when foreign sales are converted into dollars.

Human Nutrition & Health (65% of sales: nutrients such as choline and minerals, plus food and beverage ingredient systems) is where the quarter looks different from Q2. In Q2 this segment grew 10.0% with 7.0 points from volume and +2.7 points from price. In Q3 volume and mix contributed 12.7 points, but average selling prices subtracted 4.4 points, so reported sales grew a slower 8.1%. The 10-Q says growth came from "higher sales within both the nutrients business and the food ingredients and solutions businesses" but does not say why prices fell. Profit still rose $4.8 million, which the company puts down to "a gross margin contribution of $6,312 [thousand] driven by higher sales and favorable mix." The segment's gross margin widened to about 37.4% from about 36.8% despite the lower prices, which fits a pattern of passing lower costs on to customers rather than discounting into weak demand, though the filing does not state that.

Animal Nutrition & Health is now growing mostly through price. Sales rose 11.7%, with 8.5 points from higher prices and only 3.6 points from volume, across both monogastric (pigs, poultry) and ruminant (dairy cattle) markets. In Q2 the split was nearly even (7.9 points volume, 6.6 price). Operating profit rose $3.1 million to $6.8 million, mostly from a $3.2 million gross margin gain "driven by higher sales and favorable mix, partially offset by certain higher manufacturing input costs." At 10.8%, the margin is the segment's best of the year (8.1% in Q2) but still well below the other two segments.

Specialty Products (performance gases such as ethylene oxide for sterilising medical devices, and chelated minerals for crops) grew 4.5%, all from price: average selling prices added 7.6 points while volume and mix fell 2.8 points. Growth came from the performance gases business. The margin edged up to 33.0%. Volumes grew 3.7 points in Q2, so this is a reversal; over nine months volume/mix is now -0.6 points.

Where the extra profit came from

Earnings from operations rose $7.9 million. Gross margin added $10.3 million (sales growth, "favorable mix and manufacturing efficiencies, partially offset by certain higher manufacturing input costs," per the 10-Q). Operating expenses rose $2.4 million to $43.3 million, which the 10-Q breaks down as $3.7 million of higher compensation costs and a $1.9 million impairment on "certain manufacturing equipment that will not be placed into service," partly offset by a $4.0 million favourable legal settlement.

Below the operating line, net interest expense fell to $1.9 million from $2.6 million on "lower outstanding borrowings and lower interest rates." Other expense swung to a $0.5 million cost from a $0.1 million gain, mainly unrealised losses on the rabbi trust (investments held to fund executives' deferred pay). The tax rate dipped to 22.2% from 22.6% thanks to favourable true-ups on filing the prior year's federal return and a larger foreign-derived intangible income deduction.

What the headline numbers hide

About a third of the operating-profit growth was a one-off. The $4.0 million legal settlement and the $1.9 million impairment net to roughly $2.1 million of extra operating profit that will not repeat. Strip it out and earnings from operations would be about $60.4 million, up about 10.6% rather than 14.4%, and the operating margin about 20.8% rather than 21.5%. After tax at the quarter's 22.2% rate, the net one-off is worth roughly $0.05 per share, putting underlying EPS near $1.41 (about +14% rather than +17.7%). The 10-Q does not name the counterparty or which segment the settlement and impairment sit in.

The overhead leverage from Q2 did not continue. In Q2 the margin gain came from expenses growing slower than sales. In Q3, excluding the net one-off, operating expenses would have been about $45.4 million, or 15.6% of sales, slightly above last year's 15.3%. Compensation costs alone rose $3.7 million in the quarter and $11.8 million over nine months. This quarter's real margin improvement came from gross margin instead.

Buybacks and lower interest helped EPS. Diluted shares fell 1.7% to 32.0 million, so EPS (+17.7%) grew faster than net earnings (+16.0%). Balchem spent $71.9 million buying back stock in the first nine months, up from $54.0 million a year earlier. Lower interest added roughly $0.7 million before tax. Net of buybacks, the one-off and interest, operations still delivered low-double-digit profit growth.

Cash conversion is strong, but inventory keeps building. Operating cash flow for nine months was $156.5 million, 1.19 times net earnings of $131.6 million; on our numbers (subtracting the $86.8 million first-half figure), Q3 alone generated about $69.7 million. Nine-month free cash flow (operating cash flow minus $29.6 million of capital spending) was $126.9 million versus $122.0 million a year ago. But that cash was achieved despite inventory absorbing $47.3 million (against a $2.6 million release last year), because payables and accrued expenses rose $19.5 million. Inventory reached $177.0 million: raw materials up 33% since December to $55.7 million and finished goods up 35% to $112.5 million. The reserve for excess or obsolete stock rose to $5.1 million from $3.4 million in December. Receivables, by contrast, are flat at $145.6 million (vs $143.6 million in December), so this is not a case of sales being booked without cash coming in.

Did last time's read hold up?

Our Q2 2026 report listed four things to watch:

• Input costs squeezing gross margin: did not happen. Gross margin was 36.4% versus 35.7% a year ago (36.5% in Q2), although the 10-Q again mentions "certain higher manufacturing input costs."
• Animal Nutrition's margin recovery holding: held and improved, to 10.8% from 8.1% in Q2, though growth is now more price-led than volume-led.
• Inventory coming back down: it did not. It rose another $15.4 million in the quarter, to $177.0 million.
• The bigger credit line funding an acquisition: no deal yet. The new $650 million facility was used to refinance the old one, borrowing fell to $124.0 million from $152.0 million at June 30, and the 10-Q still says Balchem is "actively pursuing additional acquisition candidates."

Our Q2 estimate of roughly 10% sales growth and mid-teens EPS growth for the year is on track at nine months (+9.3% and +15.5%), though Q3 sales growth (8.6%) ran below that pace.

Takeaway: Balchem's biggest segment sold 12.7% more product in Q3 even as its prices fell 4.4%, and still widened its margin — a sign of real demand rather than price-driven growth. But part of the profit jump was a one-off legal gain, overhead is again growing faster than sales, and a 35% inventory build since December now needs either a strong Q4 or an explanation.

Balance sheet and capital

Debt is low and falling. The revolving loan stood at $124.0 million at September 30 (from $164.0 million in December), with cash of $66.3 million, so net debt (borrowings minus cash) is about $57.7 million against nine-month operating earnings of $177.3 million. On July 24, 2026 Balchem raised its credit facility from $550 million to $650 million and extended it to July 2031; $526 million was unused at quarter end, at an interest rate of 4.90%. Of the $66.3 million of cash, $57.9 million sits with foreign subsidiaries.

Risks the company flags

• Middle East conflict: the 10-Q again cites tensions involving Iran as a source of higher energy, raw material and freight costs and shipping disruption.
• Tariffs: Balchem has been claiming refunds since June 2026 for IEEPA tariffs struck down by the Supreme Court in February 2026; it does not expect the impact to be material.
• Ethylene oxide regulation remains a standing risk to the sterilisation-gas business in Specialty Products, which also saw volumes decline this quarter.

Outlook

Balchem gives no numerical guidance in the 10-Q. Our read: the business is on course for about 9% sales growth and mid-teens EPS growth in 2026, but Q3 shows growth becoming more dependent on price in two of three segments (Animal Nutrition and Specialty Products) and on a one-off gain at the operating line. The things to watch in the Q4/full-year report (Balchem's 10-K usually arrives in late February) are whether Human Nutrition's volume gains continue as prices fall, whether Specialty Products' volume decline was a one-quarter dip, whether inventory finally starts to come down, and whether the larger credit line is put towards the acquisition management keeps saying it is pursuing.